文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

IL-6拮抗剂与COVID-19住院患者死亡率的关系:一项荟萃分析

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.
PubMed 文献 · JAMA · 2021-01-01
一句话结论在COVID-19住院患者中,IL-6拮抗剂(主要为托珠单抗)与28天全因死亡率降低相关(OR 0.86),但沙利鲁单抗无此关联。

28天全因死亡率在IL-6拮抗剂组为22%,对照组假设为25%(汇总OR 0.86,95%CI 0.79-0.95;托珠单抗亚组OR 0.83(95%CI 0.74-0.92),沙利鲁单抗OR 1.08(95%CI 0.86-1.36)。接受皮质类固醇者中托珠单抗OR 0.77(95%CI 0.68-0.87)。

要点

  • 在接受皮质类固醇的患者中,托珠单抗与死亡率降低相关:OR 0.77(95%CI 0.68-0.87);沙利鲁单抗OR 0.92(95%CI 0.61-1.38)。
  • IL-6拮抗剂整体与进展至有创机械通气或死亡风险降低相关:OR 0.77(95%CI 0.70-0.85);托珠单抗OR 0.74(95%CI 0.66-0.82);沙利鲁单抗OR 1.00(95%CI 0.74-1.34)。
  • 28天内继发感染在IL-6拮抗剂组为21.9%,对照组为17.6%(考虑试验样本量的OR 0.99;95%CI 0.85-1.16)。

适用人群与场景

  • 排除(对照条件):对照组不使用IL-6拮抗剂,也不使用除皮质类固醇以外的任何其他免疫调节剂。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及具体药物剂量、给药途径、频次或疗程;仅报告了托珠单抗和沙利鲁单抗的汇总效应,未给出床旁用药方案。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 接受皮质类固醇者中:托珠单抗与死亡率OR 0.77(95%CI 0.68-0.87);沙利鲁单抗OR 0.92(95%CI 0.61-1.38)。
  • 次要终点:进展至有创机械通气或死亡,所有IL-6拮抗剂OR 0.77(95%CI 0.70-0.85);托珠单抗OR 0.74(95%CI 0.66-0.82);沙利鲁单抗OR 1.00(95%CI 0.74-1.34)。
  • 不良事件:28天内继发感染,IL-6拮抗剂组21.9% vs 对照组17.6%(考虑试验样本量的OR 0.99;95%CI 0.85-1.16)。

证据类型、等级与局限

  • 证据类型:前瞻性荟萃分析(纳入27项随机试验);使用Cochrane偏倚风险评估工具评估偏倚风险,用I2统计量评估异质性;主要分析为逆方差加权固定效应模型。
  • 局限:原文未明确列出局限;设计上为荟萃分析,纳入试验存在异质性(I2未在摘要中报告),沙利鲁单抗亚组样本量较小且置信区间宽。

对床旁实践的改变

  • 在COVID-19住院患者中,IL-6拮抗剂(尤其托珠单抗)可考虑用于降低28天全因死亡率,但沙利鲁单抗未显示获益。
  • 接受皮质类固醇的患者中,托珠单抗仍与死亡率降低相关(OR 0.77),支持在与皮质类固醇联用时考虑托珠单抗。
  • 使用IL-6拮抗剂时需注意继发感染风险(21.9% vs 17.6%),但原文报告校正样本量后OR 0.99(95%CI 0.85-1.16),未明确增加风险。
  • 原文未提供具体用药剂量、疗程及患者选择标准,床旁决策需结合具体试验方案和当地指南。

指南或共识出处

  • 原文未提及指南或共识名称;本文为荟萃分析,试验注册号PROSPERO CRD42021230155。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized for COVID-19 have variously reported benefit, no effect, and harm.

OBJECTIVE: To estimate the association between administration of IL-6 antagonists compared with usual care or placebo and 28-day all-cause mortality and other outcomes.

DATA SOURCES: Trials were identified through systematic searches of electronic databases between October 2020 and January 2021. Searches were not restricted by trial status or language. Additional trials were identified through contact with experts.

STUDY SELECTION: Eligible trials randomly assigned patients hospitalized for COVID-19 to a group in whom IL-6 antagonists were administered and to a group in whom neither IL-6 antagonists nor any other immunomodulators except corticosteroids were administered. Among 72 potentially eligible trials, 27 (37.5%) met study selection criteria.

DATA EXTRACTION AND SYNTHESIS: In this prospective meta-analysis, risk of bias was assessed using the Cochrane Risk of Bias Assessment Tool. Inconsistency among trial results was assessed using the I2 statistic. The primary analysis was an inverse variance-weighted fixed-effects meta-analysis of odds ratios (ORs) for 28-day all-cause mortality.

MAIN OUTCOMES AND MEASURES: The primary outcome measure was all-cause mortality at 28 days after randomization. There were 9 secondary outcomes including progression to invasive mechanical ventilation or death and risk of secondary infection by 28 days.

RESULTS: A total of 10 930 patients (median age, 61 years [range of medians, 52-68 years]; 3560 [33%] were women) participating in 27 trials were included. By 28 days, there were 1407 deaths among 6449 patients randomized to IL-6 antagonists and 1158 deaths among 4481 patients randomized to usual care or placebo (summary OR, 0.86 [95% CI, 0.79-0.95]; P = .003 based on a fixed-effects meta-analysis). This corresponds to an absolute mortality risk of 22% for IL-6 antagonists compared with an assumed mortality risk of 25% for usual care or placebo. The corresponding summary ORs were 0.83 (95% CI, 0.74-0.92; P < .001) for tocilizumab and 1.08 (95% CI, 0.86-1.36; P = .52) for sarilumab. The summary ORs for the association with mortality compared with usual care or placebo in those receiving corticosteroids were 0.77 (95% CI, 0.68-0.87) for tocilizumab and 0.92 (95% CI, 0.61-1.38) for sarilumab. The ORs for the association with progression to invasive mechanical ventilation or death, compared with usual care or placebo, were 0.77 (95% CI, 0.70-0.85) for all IL-6 antagonists, 0.74 (95% CI, 0.66-0.82) for tocilizumab, and 1.00 (95% CI, 0.74-1.34) for sarilumab. Secondary infections by 28 days occurred in 21.9% of patients treated with IL-6 antagonists vs 17.6% of patients treated with usual care or placebo (OR accounting for trial sample sizes, 0.99; 95% CI, 0.85-1.16).

CONCLUSIONS AND RELEVANCE: In this prospective meta-analysis of clinical trials of patients hospitalized for COVID-19, administration of IL-6 antagonists, compared with usual care or placebo, was associated with lower 28-day all-cause mortality.

TRIAL REGISTRATION: PROSPERO Identifier: CRD42021230155.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Shankar-Hari M, Vale CL, Godolphin PJ, et al. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA. 2021. PMID: 34228774. doi:10.1001/jama.2021.11330

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。